Studies in endocrinology, diabetology
with ongoing recruitmentD6973C00001 BaxDuo Prevent-HF
| Target group: | Patients with type 2 diabetes mellitus and known concomitant cardiovascular disease (myocardial infarction, stroke, circulatory disorders) |
| Aim of the study: | Investigation of the efficacy of baxdrostat/dapagliflozin compared to placebo/dapagliflozin in preventing the development of heart failure (cardiac insufficiency) |
| Contact person: | Prof. Dr. med. Jochen Seufert |
Study Assistance Contact | +49 (0) 761 270-32618 |
Project Coordination Contact | +49 (0) 761 270-32613 +49 (0) 761 270-32622 |